Develops peptide therapeutics for sexual dysfunction disorders and other metabolic diseases.
Palatin Technologies, Inc. is a leading biopharmaceutical company based in Cranbury, New Jersey, dedicated to pioneering targeted receptor-specific therapies for various diseases across the United States. The company's primary focus is on Vyleesi, its flagship product and a melanocortin receptor (MCr) agonist designed for the treatment of hypoactive sexual desire disorder in premenopausal women. Palatin Technologies also advances oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trials, targeting inflammatory bowel diseases.
In addition to its innovative therapies in sexual health and inflammatory conditions, Palatin Technologies is actively developing PL9643, a peptide melanocortin agonist with applications in ocular anti-inflammatory indications like dry eye disease, leveraging its broad-spectrum activity across multiple MCrs including MC1r and MC5r. The company's pipeline further includes PL3994, a peptide mimetic molecule designed with amino acid properties, and L8177, an oral peptide formulation currently in Phase 2 clinical trials for treating ulcerative colitis.
Founded in 1986, Palatin Technologies has established itself as a leader in biopharmaceutical research and development, continually pushing the boundaries of therapeutic innovation. With a commitment to addressing unmet medical needs through targeted therapies, the company remains at the forefront of advancing treatments that enhance patient outcomes and quality of life.